#USA #New York #Class Action #Pomerantz LLP #Applied Therapeutics

Pomerantz Law Firm Encourages Action from Applied Therapeutics Shareholders

Pomerantz LLP, a renowned law firm, is making waves in the investment community as it brings attention to its recently filed class action lawsuit against Applied Therapeutics, Inc. (NASDAQ: APLT). Shareholders who have suffered financial losses are being urged to reach out to the firm before the approaching deadlines, particularly the lead plaintiff application deadline of February 18, 2025.

Overview of the Class Action Lawsuit

As investors grapple with the financial fallout from their investments in Applied Therapeutics, the Pomerantz law firm aims to address potential security fraud and unlawful business practices that may have adversely affected shareholders. These issues came to light following a concerning press release from Applied Therapeutics on November 27, 2024, when the company announced receiving a Complete Response Letter (CRL) from the FDA regarding its New Drug Application (NDA) for the drug govorestat, designed to treat Classic Galactosemia.

The news was met with significant market reaction, causing Applied Therapeutics' stock to plunge by $1.64, or approximately 16.06%, closing at $8.57 that day. This stark decline raised alarms among investors and prompted Pomerantz LLP to act.

Regulatory Challenges Unfold

Following the initial CRL, Applied Therapeutics encountered further trouble on December 2, 2024, when the company disclosed that they received a warning letter from the FDA. This letter flagged issues related to their clinical trials, complicating matters for the company even further. The FDA's warning specifically addressed concerns about electronic data capture and a dosing error during the trial's dose-escalation phase. In the wake of this news, shares of Applied Therapeutics dropped again, leading to a dramatic fall to $1.29 per share within just a few trading sessions.

Taking Action as a Shareholder

For investors affected by these recent events, time is of the essence. Pomerantz LLP is encouraging those who purchased or acquired shares during the Class Period to contact Danielle Peyton at the firm. Those interested in joining the action as a lead plaintiff are advised to respond quickly, emphasizing the importance of acting before the February deadline. With a strong track record of securing billions in damages for investors, Pomerantz is committed to safeguarding the rights of shareholders navigating the turbulent waters of corporate misconduct and securities fraud.

A Legacy in Class Action Litigation

Founded by Abraham L. Pomerantz, recognized as a pioneer of the class action bar, the firm has established itself as one of the leading entities in corporate and securities class litigation. With over 85 years of experience, Pomerantz continues to uphold its founding ideals, championing the victims of securities fraud and other forms of corporate malfeasance.

Stakeholders are encouraged to stay informed about ongoing developments and to carefully consider their options. Further information about the class action and how to participate can be obtained through Pomerantz's official website.

In conclusion, as Applied Therapeutics faces significant regulatory hurdles, shareholders have a critical opportunity to engage and potentially recoup some of their investments before it’s too late. The class action represents a necessary avenue for those seeking justice and accountability amid the challenges posed by the current market conditions.